Jun 02, 2025
Immutep Corporate Presentation
Dec 12, 2024
ESMO Immuno-Oncology 2024 – TACTI-003, Cohort B (Metastatic Head and Neck Squamous Cell Carcinoma)
Nov 22, 2024
2024 AGM CEO Presentation
Nov 13, 2024
CTOS 2024 Annual Meeting – EFTISARC-NEO trial of neoadjuvant soluble LAG-3 protein (Soft Tissue Sarcoma)
Sep 15, 2024
ESMO Congress 2024 – TACTI-003, Cohort A (Head and Neck Squamous Cell Carcinoma)
Jul 12, 2024
ESMO Virtual Plenary 2024 – TACTI-003, Cohort B (Head and Neck Squamous Cell Carcinoma)
Jul 11, 2024
Global Webcast Slides for TACTI-003 Positive Data in Patients with Negative PD-L1 Expression (Cohort B)
Jun 26, 2024
Immutep Global Webcast Slides for New Efti Clinical Data in 1st Line HNSCC
May 15, 2024
ESMO Breast 2024 – AIPAC-003 Poster (Metastatic Breast Cancer)
Nov 13, 2023
Targets & Cell Types In Immuno-Oncology Europe 2023
Nov 03, 2023
SITC 2023 – TACTI-002 Poster (First Line Metastatic Non-Small Cell Lung Cancer)
Oct 24, 2023
2023 AGM CEO Presentation
Oct 23, 2023
ESMO 2023 – INSIGHT-003 Poster (Metastatic Non-Small Cell Lung Cancer)
ESMO 2023 – EFTISARC-NEO Trial in Progress Poster (Soft Tissue Sarcoma)
Oct 22, 2023
Immutep Global Webcast Slides: Update on New Data in First Line Treatment of Metastatic NSCLC at ESMO 2023
